Does the media prefer BAX or AMN?

In the previous week, Baxter International had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 13 mentions for Baxter International and 7 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.52 beat Baxter International's score of 0.10 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AMN Healthcare Services 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DVA or BAX?

In the previous week, Baxter International had 9 more articles in the media than DaVita. MarketBeat recorded 13 mentions for Baxter International and 4 mentions for DaVita. DaVita's average media sentiment score of 0.46 beat Baxter International's score of 0.10 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Baxter International 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IDXX or BAX?

In the previous week, Baxter International had 6 more articles in the media than IDEXX Laboratories. MarketBeat recorded 13 mentions for Baxter International and 7 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.34 beat Baxter International's score of 0.10 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BAX or DXCM?

In the previous week, Baxter International had 1 more articles in the media than DexCom. MarketBeat recorded 13 mentions for Baxter International and 12 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Baxter International's score of 0.10 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RMD or BAX?

In the previous week, Baxter International had 7 more articles in the media than ResMed. MarketBeat recorded 13 mentions for Baxter International and 6 mentions for ResMed. ResMed's average media sentiment score of 0.64 beat Baxter International's score of 0.10 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Baxter International (BAX) Competitors

$24.33 +0.43 (+1.81%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$24.22 -0.11 (-0.44%)

As of 10/9/2026 07:52 PM Eastern

Compare

BAX vs. AMN, DVA, IDXX, DXCM, and RMD

Should you buy Baxter International stock or one of its competitors? Baxter International's main competitors and comparable companies include AMN Healthcare Services (AMN), DaVita (DVA), IDEXX Laboratories (IDXX), DexCom (DXCM), and ResMed (RMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Baxter International compare to AMN Healthcare Services?

Baxter International (NYSE:BAX) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Baxter International has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

AMN Healthcare Services has a net margin of 3.06% compared to Baxter International's net margin of -9.27%. AMN Healthcare Services' return on equity of 19.92% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.27%	16.57%	5.24%
AMN Healthcare Services	3.06%	19.92%	5.93%

Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. AMN Healthcare Services pays an annual dividend of $1.20 per share and has a dividend yield of 3.3%. Baxter International pays out -1.9% of its earnings in the form of a dividend. AMN Healthcare Services pays out 44.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Baxter International presently has a consensus price target of $21.73, indicating a potential downside of 10.70%. AMN Healthcare Services has a consensus price target of $36.50, indicating a potential downside of 0.18%. Given AMN Healthcare Services' stronger consensus rating and higher probable upside, analysts clearly believe AMN Healthcare Services is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.85
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

AMN Healthcare Services has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A
AMN Healthcare Services	$3.43B	0.41	-$95.70M	$2.68	13.64

90.2% of Baxter International shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Baxter International had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 13 mentions for Baxter International and 7 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.52 beat Baxter International's score of 0.10 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AMN Healthcare Services	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AMN Healthcare Services beats Baxter International on 13 of the 18 factors compared between the two stocks.

How does Baxter International compare to DaVita?

DaVita (NYSE:DVA) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

DaVita has a net margin of 6.05% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Baxter International	-9.27%	16.57%	5.24%

DaVita has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

90.1% of DaVita shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 1.9% of DaVita shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Baxter International had 9 more articles in the media than DaVita. MarketBeat recorded 13 mentions for Baxter International and 4 mentions for DaVita. DaVita's average media sentiment score of 0.46 beat Baxter International's score of 0.10 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Baxter International	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

DaVita presently has a consensus target price of $233.43, indicating a potential upside of 30.43%. Baxter International has a consensus target price of $21.73, indicating a potential downside of 10.70%. Given DaVita's stronger consensus rating and higher probable upside, research analysts plainly believe DaVita is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Baxter International	3 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.85

DaVita has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.84	$746.80M	$12.22	14.65
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A

Summary

DaVita beats Baxter International on 11 of the 16 factors compared between the two stocks.

How does Baxter International compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

IDEXX Laboratories has a net margin of 25.03% compared to Baxter International's net margin of -9.27%. IDEXX Laboratories' return on equity of 71.96% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Baxter International	-9.27%	16.57%	5.24%

IDEXX Laboratories presently has a consensus price target of $747.00, indicating a potential upside of 44.21%. Baxter International has a consensus price target of $21.73, indicating a potential downside of 10.70%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Baxter International	3 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.85

IDEXX Laboratories has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.55B	8.96	$1.06B	$14.22	36.43
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IDEXX Laboratories has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

In the previous week, Baxter International had 6 more articles in the media than IDEXX Laboratories. MarketBeat recorded 13 mentions for Baxter International and 7 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.34 beat Baxter International's score of 0.10 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IDEXX Laboratories beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does Baxter International compare to DexCom?

Baxter International (NYSE:BAX) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, Baxter International had 1 more articles in the media than DexCom. MarketBeat recorded 13 mentions for Baxter International and 12 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Baxter International's score of 0.10 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a net margin of 20.12% compared to Baxter International's net margin of -9.27%. DexCom's return on equity of 35.94% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.27%	16.57%	5.24%
DexCom	20.12%	35.94%	14.75%

Baxter International has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, DexCom has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DexCom has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A
DexCom	$4.97B	6.39	$836.30M	$2.53	33.25

Baxter International presently has a consensus price target of $21.73, indicating a potential downside of 10.70%. DexCom has a consensus price target of $91.96, indicating a potential upside of 9.33%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.85
DexCom	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	3.04

Summary

DexCom beats Baxter International on 15 of the 17 factors compared between the two stocks.

How does Baxter International compare to ResMed?

ResMed (NYSE:RMD) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. ResMed pays out 25.3% of its earnings in the form of a dividend. Baxter International pays out -1.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Baxter International had 7 more articles in the media than ResMed. MarketBeat recorded 13 mentions for Baxter International and 6 mentions for ResMed. ResMed's average media sentiment score of 0.64 beat Baxter International's score of 0.10 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ResMed has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.6% of ResMed shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ResMed currently has a consensus price target of $241.69, suggesting a potential upside of 5.10%. Baxter International has a consensus price target of $21.73, suggesting a potential downside of 10.70%. Given ResMed's stronger consensus rating and higher probable upside, research analysts plainly believe ResMed is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Baxter International	3 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.85

ResMed has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.72	$1.52B	$10.43	22.05
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A

ResMed has a net margin of 26.94% compared to Baxter International's net margin of -9.27%. ResMed's return on equity of 25.58% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Baxter International	-9.27%	16.57%	5.24%

Summary

ResMed beats Baxter International on 15 of the 19 factors compared between the two stocks.

Get Baxter International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BAX vs. The Competition

Export

Metric	Baxter International	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.59B	$5.51B	$7.26B	$23.07B
Dividend Yield	0.16%	1.76%	2.52%	3.72%
P/E Ratio	-11.75	20.88	201.60	23.78
Price / Sales	1.12	71.61	581.89	21.85
Price / Cash	4.28	32.11	76.96	38.93
Price / Book	2.05	5.95	11.22	4.72
Net Income	-$957M	$146.18M	$3.50B	$1.07B
7 Day Performance	3.62%	-0.28%	-0.89%	0.35%
1 Month Performance	0.67%	-1.88%	-4.42%	-2.94%
1 Year Performance	10.88%	5.45%	7.03%	9.25%

Baxter International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BAX Baxter International	1.1589 of 5 stars	$24.33 +1.8%	$21.73 -10.7%	+8.2%	$12.59B	$11.24B	N/A	37,500	News Coverage Analyst Forecast
AMN AMN Healthcare Services	1.3363 of 5 stars	$36.83 +0.6%	$36.00 -2.3%	+93.1%	$1.42B	$2.73B	13.74	2,664	Analyst Forecast Gap Up
DVA DaVita	4.5648 of 5 stars	$178.56 -0.1%	$233.43 +30.7%	+41.7%	$11.40B	$13.64B	14.61	78,000	News Coverage Analyst Upgrade
IDXX IDEXX Laboratories	4.6083 of 5 stars	$527.07 +1.7%	$747.00 +41.7%	-17.6%	$40.84B	$4.30B	37.07	11,000	Positive News Analyst Upgrade
DXCM DexCom	4.6549 of 5 stars	$86.90 +1.8%	$89.74 +3.3%	+23.5%	$32.21B	$4.66B	34.35	11,000	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BAX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, IDXX, DXCM, and RMD

How does Baxter International compare to AMN Healthcare Services?

Summary

How does Baxter International compare to DaVita?

Summary

How does Baxter International compare to IDEXX Laboratories?

Summary

How does Baxter International compare to DexCom?

Summary

How does Baxter International compare to ResMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, IDXX, DXCM, and RMD

How does Baxter International compare to AMN Healthcare Services?

Which has more volatility and risk, BAX or AMN?

Is BAX or AMN more profitable?

Is BAX or AMN a better dividend stock?

Do analysts rate BAX or AMN?

Which has better valuation & earnings, BAX or AMN?

Do insiders and institutionals have more ownership in BAX or AMN?

Does the media prefer BAX or AMN?

Summary

How does Baxter International compare to DaVita?

Is DVA or BAX more profitable?

Which has more risk & volatility, DVA or BAX?

Do insiders & institutionals believe in DVA or BAX?

Does the media favor DVA or BAX?

Do analysts prefer DVA or BAX?

Which has preferable earnings & valuation, DVA or BAX?

Summary

How does Baxter International compare to IDEXX Laboratories?

Is IDXX or BAX more profitable?

Do analysts rate IDXX or BAX?

Which has stronger earnings & valuation, IDXX or BAX?

Do insiders and institutionals have more ownership in IDXX or BAX?

Which has more risk and volatility, IDXX or BAX?

Does the media prefer IDXX or BAX?

Summary

How does Baxter International compare to DexCom?

Does the media prefer BAX or DXCM?

Is BAX or DXCM more profitable?

Which has more risk & volatility, BAX or DXCM?

Do institutionals & insiders believe in BAX or DXCM?

Which has better earnings & valuation, BAX or DXCM?

Do analysts prefer BAX or DXCM?

Summary

How does Baxter International compare to ResMed?

Is RMD or BAX a better dividend stock?

Does the media prefer RMD or BAX?

Which has more risk and volatility, RMD or BAX?

Do insiders and institutionals have more ownership in RMD or BAX?

Do analysts recommend RMD or BAX?

Which has preferable valuation & earnings, RMD or BAX?

Is RMD or BAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools